A New Patient Voice In The Medicare/Alzheimer’s Drug Coverage Debate
Executive Summary
Individuals with Down syndrome are particularly vulnerable to the disease yet would be excluded from participating in clinical trials described in the draft Medicare coverage policy for Alzheimer’s drugs.
You may also be interested in...
Medicare Alzheimer’s Decision Varies Evidence Mandate For Accelerated vs. Traditional Approvals
Final Medicare national coverage determination aims to set up a ‘nimble’ system to allow for broad and rapid patient access to drugs for Alzheimer’s disease following traditional approval while retaining a more restrictive approach for accelerated approvals.
Medicare Alzheimer's Drug Study Criteria Would Be Out Of Reach In Many States – Analysis
Alzheimer's patient groups continue to argue against the CMS draft national coverage determination on Aduhelm, but effort to meet with HHS Secretary Xavier Becerra is thwarted.
Medicare And Alzheimer's Drugs: Grassroots Campaign Opposing Coverage Aims To ‘Take On Big Pharma’
Nearly 5,000 comments from individuals on CMS’ proposal to restrict coverage of Alzheimer’s drugs argue that Aduhelm should never have been approved and should not be covered. The outpouring is surprising in light of expectations there would be a flood of patient comments urging broader coverage.